Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）
摘要
T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab. Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone.
更多查看译文
关键词
advanced melanoma,talimogene laherparepvec combined,pembrolizumab,global phase iii trial,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要